AGEN logo

Agenus Inc.

AGEN

AGEN: Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

more

Show AGEN Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of AGEN by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by AGEN's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard
Corporate Lobbying

Government lobbying spending instances

  • $10,000 Jul 20, 2018 Issue: Medical/Disease Research/Clinical Labs
  • $10,000 Apr 20, 2018 Issue: Medical/Disease Research/Clinical Labs
  • $10,000 Jan 18, 2018 Issue: Medical/Disease Research/Clinical Labs
  • $10,000 Oct 20, 2017 Issue: Medical/Disease Research/Clinical Labs
U.S. Patents

New patents grants

  • Patent Title: Anti-tigit and anti-cd96 antibodies Aug. 08, 2023
  • Patent Title: Anti-cd73 antibodies and methods of use thereof Jul. 04, 2023
  • Patent Title: Antibodies that specifically bind human cd96 Jun. 20, 2023
  • Patent Title: Anti-ctla-4 antibodies and methods of use thereof May. 02, 2023
  • Patent Title: Methods of administering anti-ox40 antibodies Oct. 18, 2022
  • Patent Title: Antibodies and methods of use thereof Sep. 20, 2022
  • Patent Title: Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies Aug. 16, 2022
  • Patent Title: Anti-gitr antibodies and methods of use thereof Aug. 02, 2022
  • Patent Title: Anti-ox40 antibodies and anti-gitr antibodies Jun. 14, 2022
  • Patent Title: Anti-pd-1 antibodies and methods of use thereof May. 31, 2022
  • Patent Title: Vectors comprising nucleic acids encoding anti-ox40 antibodies May. 17, 2022
  • Patent Title: Anti-ctla-4 antibodies and methods of use thereof Mar. 08, 2022
  • Patent Title: Anti-cd137 antibodies and methods of use thereof Feb. 08, 2022
  • Patent Title: Anti-ox40 antibodies Oct. 05, 2021
  • Patent Title: Anti-cd137 antibodies and methods of use thereof Aug. 24, 2021
  • Patent Title: Heat shock protein-binding peptide compositions and methods of use thereof Jul. 20, 2021
  • Patent Title: Anti-tigit antibodies and methods of use thereof Jun. 01, 2021
  • Patent Title: Anti-ctla-4 antibodies and methods of use thereof May. 25, 2021
  • Patent Title: Anti-ctla-4 antibodies and methods of use thereof Feb. 09, 2021
  • Patent Title: Anti-tim-3 antibodies and methods of use thereof Feb. 09, 2021
  • Patent Title: Anti-lag-3 antibodies and methods of use thereof Jan. 05, 2021
  • Patent Title: Anti-lag-3 antibodies and methods of use thereof Nov. 24, 2020
  • Patent Title: Antibodies and methods of use thereof Nov. 17, 2020
  • Patent Title: Anti-gitr antibodies and methods of use thereof Nov. 10, 2020
  • Patent Title: Anti-gitr antibodies and methods of use thereof Oct. 13, 2020
  • Patent Title: Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies May. 05, 2020
  • Patent Title: Anti-tim-3 antibodies and methods of use thereof May. 05, 2020
  • Patent Title: Anti-gitr antibodies and methods of use thereof Mar. 03, 2020
  • Patent Title: Vaccines for treatment and prevention of cancer Feb. 25, 2020
  • Patent Title: Identification of antigen- or ligand-specific binding proteins Dec. 10, 2019
  • Patent Title: Anti-ctla-4 antibodies and methods of use thereof Nov. 19, 2019
  • Patent Title: Anti-pd-1 antibodies and methods of use thereof Oct. 22, 2019
  • Patent Title: Anti-pd-1 antibodies and methods of use thereof Jun. 18, 2019
  • Patent Title: Anti-gitr antibodies and methods of use thereof May. 07, 2019
  • Patent Title: Anti-ox40 antibodies Apr. 16, 2019
  • Patent Title: Anti-gitr antibodies and methods of use thereof Dec. 18, 2018
  • Patent Title: Anti-ctla-4 antibodies and methods of use thereof Dec. 04, 2018
  • Patent Title: Cell surface display, screening and production of proteins of interest May. 09, 2017
  • Patent Title: Identification of antigen or ligand-specific binding proteins Mar. 14, 2017
  • Patent Title: Vaccine for treatment and prevention of herpes simplex virus infection Sep. 24, 2013
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of AGEN in WallStreetBets Daily Discussion

AGEN News

Recent insights relating to AGEN

CNBC Recommendations

Recent picks made for AGEN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in AGEN

Corporate Flights

Flights by private jets registered to AGEN